Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria

Alexion Pharmaceuticals announced the presentation of new data demonstrating that ULTOMIRIS (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks, provided consistent efficacy and safety through 52 weeks in the extension of the Phase 3 study of ULTOMIRIS and SOLIRIS (eculizumab) in complement inhibitor-naïve, adult patients with paroxysmal nocturnal hemoglobinuria (PNH).